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Detection of relevant colonic neoplasms
with PET/CT: promising accuracy
with minimal CT dose and a standardised
PET cut-off
Abstract
Objective: To determine the perform-
ance of FDG-PET/CT in the detection
of relevant colorectal neoplasms
(adenomas ≥10mm, with high-grade
dysplasia, cancer) in relation to CT
dose and contrast administration and to
ﬁnd a PETcut-off. Methods: 84
patients, who underwent PET/CT and
colonoscopy (n=79)/sigmoidoscopy
(n=5) for 79   6 þ 5   2 ðÞ ¼ 484
colonic segments, were included in a
retrospective study. The accuracy of
low-dose PET/CT in detecting mass-
positive segments was evaluated by
ROC analysis by two blinded inde-
pendent reviewers relative to contrast-
enhanced PET/CT. On a per-lesion
basis characteristic PET values were
tested as cut-offs. Results: Low-dose
PET/CT and contrast-enhanced PET/
CT provide similar accuracies (area
under the curve for the average ROC
ratings 0.925 vs. 0.929, respectively).
PET demonstrated all carcinomas
(n=23) and 83% (30/36) of relevant
adenomas. In all carcinomas and
adenomas with high-grade dysplasia
(n=10) the SUVmax was ≥5. This cut-
off resulted in a better per-segment
sensitivity and negative predictive
value (NPV) than the average PET/
CT reviews (sensitivity: 89% vs.
82%; NPV: 99% vs. 98%). All other
tested cut-offs were inferior to the
SUVmax. Conclusion: FDG-PET/CT
provides promising accuracy for
colorectal mass detection. Low dose
and lack of iodine contrast in the CT
component do not impact the accu-
racy. The PET cut-off SUVmax≥5
improves the accuracy.
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Abbreviations
AUC area under the curve
CAD computer-aided detection
CUP cancer of unknown primary
CEA carcinoembryonic antigen
CTC computed tomography
colonography
MIP maximum intensity projection
MPR multiplanar reconstruction
MRC magnetic resonance
colonography
FDG 2-[
18F]ﬂuoro-2-deoxy-D-
glucose (FDG)
PET/
CT
positron emission tomography/
computed tomography
ROC receiver operating curve
SUV standardised uptake value
VOI volume of interest
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Colorectal cancer is a leading cause of morbidity and
mortality worldwide [1], despite being curable if detected
early and even preventable if dysplastic adenomas as their
precursors are eliminated [2–4]. Thus, colorectal screening
has been shown to reduce the risk of dying from colorectal
cancer. Consequently, colonoscopy was recommended
early on for colorectal screening [5]. In 1996 computed
tomography colonography (CTC) [6] and in 1997 magnetic
resonance colonography (MRC) [7] were also proposed for
colorectal screening. They have several advantages: mini-
mally invasive, fast, detect extracolonic disease, and allow
computer-aided detection. CT colonography has been
recommended in the colorectal screening guidelines since
2008 [8].
With FDG-PET/CTanother fascinating tool for colorectal
screening is on the horizon. FDG-PETexploits the increased
rate of glycolysis in tumour cells to detect diseases. FDG is
a glucose analogue that is taken up by cellular glucose
transport mechanisms. In the cell, FDG is phosphorylated
by hexokinase. In most malignant cells, FDG-6-phosphate
then becomes metabolically “trapped” intracellularly
because of the relative lack of glucose-6-phosphatase activity
in tumours. Thus, FDG accumulation mostly correlates with
the grading and the degree of malignancy. Thus, in conjunc-
tion with CT, PET/CT brings the advantage of combining
metabolic and structural information.
Because only 2.5 polyps in 1,000 develop into cancer
per year [9, 10]a n db e c a u s es i z ea n ds h a p ea r et h eo n l y
adequate predictive in vivo criteria for malignancy, PET
information about the glucose metabolism could help in
identifying relevant colorectal lesions that require poly-
pectomy or resection [5]. Through neglecting PET-negative
lesions unnecessary colonoscopies and polypectomies
might possibly be prevented. The feasibility of combining
PET and CT colonography into PET/CT colonography has
been already shown in patients with full-dose CT for
tumour staging [11, 12].
The purpose of this study was (a) to determine the
performance of FDG-PET/CT in the detection of relevant
colorectal neoplasms (adenomas ≥10 mm, with high-grade
dysplasia or cancer) in relation to the CT dose and iodine
contrast administration and (b) to ﬁnd a standardised cut-
off in PET which might serve as a basis for future
computer-aided detection (CAD) applications.
Materials and methods
Patients
In a retrospective study approved by the institutional Ethics
Committee, 4,004 consecutive FDG-PET/CT reports from
2,735 patients examined in the period from May 2005 to
May 2009 at the University Hospital of Dresden were
browsed for those patients who had either a colorectal
cancer, a cancer of unknown primary (CUP) syndrome, or
focal colorectal FDG uptake further evaluated by colono-
scopy or sigmoidoscopy.
PET/CT protocol
PET/CT was performed from the skull base through to the
mid-thigh on a 16-slice PET/CT (Biograph 16, Siemens
Medical Solutions) and included:
1. Low-dose (<1 mSv) CT (10 mAs, 120 kV, 16×
1.5 mm collimation, 0.42 s tube rotation time, 86 mm/
s table feed) for attenuation correction, and/or
2. Normal-dose CT (100 mAs (care dose), 120 kV, 16×
1.5 mm collimation, 0.75 s tube rotation time, 48 mm/
s table feed) with contrast enhancement in the portal
venous phase (370 mg/ml iodine concentration,
120 ml contrast volume, 3 ml/s ﬂow, 55 s delay,
30 ml saline ﬂush with 1.5 ml/s ﬂow) and
3. PET following 74±12 min after the injection of 327±
48 MBq FDG with 7–8 table positions each 3 min.
PET images were iteratively reconstructed with 5-mm-
thick slices. CT images were reconstructed with 2.5-mm-
thick slices.
The bowel was completely unprepped i.e. not cleansed,
not distended and not relaxed with spasmolytics (Figs. 1,
2, 3). Only negative oral contrast material was given.
In order to increase the number of patients in the
analysis also the PET/CT databank of the university
hospital Frankfurt was browsed for patients fulﬁlling the
inclusion criteria described above.
Interpretation
Examinations were analysed qualitatively on a per-seg-
ment basis and quantitatively on a per-lesion basis.
The qualitative analysis was blindly performed by two
independent physicians—a radiologist experienced in CT
colonography and less experienced in PET (R1) and a
nuclear medicine physician experienced in PET and less
experienced in CT (R2). They assessed the PET/CT on a
commercially available workstation (Advantage Windows
4.4, General Electric) with two screens each with a
quadrant display. The ﬁr s ts c r e e ns h o w e do n l yP E T
images: a rotating maximal intensity projection (MIP)
(Fig. 1) in the upper left corner and the orthogonal
(coronal, axial and sagittal) multiplanar reconstructions
(MPRs) in the other three quadrants. The second screen
showed three orthogonal MPRs of the PET/CT and a
coronal CT in a lung window. For reviewing PET alone
the second computer screen showing the PET/CTwas shut
down. This ensured that the PET was reviewed separately
from the CT in order to compare the subjective PET
reviewing with the cut-off-based PET analysis.
The rotating MIP of the PET was used to screen for
increased FDG uptake in the abdomen (Fig. 1). Once
2275increased FDG uptake was found, the reviewer placed a
cross-reference on the lesion which automatically showed
the lesion on the three MPRs of the PET. By scrolling
through the MPRs and following the course of the
colon the reviewer had to decide if the lesion was in or
outside the colon. If the lesion was considered to be in the
colon, the reviewer had to assign the lesion to one of the
six colonic segments (caecum, ascending, transverse and
descending colon, sigmoid and rectum). Subsequently the
reviewer had to rate the probability of the colonic segment
being mass-positive on a ﬁve-point scale (1 = deﬁnitely
negative, 2 = probably negative, 3 = equivocal, 4 = probably
positive, 5 = deﬁnitely positive). Segments without increased
FDG uptake were rated as deﬁnitely negative.
First PET was reviewed alone, then the second screen
was turned on and PET was reviewed in combination with
low-dose CTas PET/CT. CTwas used to decide if the PET
lesion was in or outside the colon and if the PET lesion had
a sphincter, stool, collapsed bowel or an inﬂammation as a
false-positive correlate. Finally low-dose CT was replaced
by contrast-enhanced CT for evaluating contrast-enhanced
PET/CT.
Measurements of Hounsﬁeld units (HU) were used to
prove stool by air inclusions (minimum HU<0) or a mass
by a mean contrast enhancement ΔHU ¼ HUwith contrast  ð ð
HUwithout contrastÞ > 20HUÞ.
If a wall-adherent mass could be identiﬁed on CT
(Fig. 3), its height and length were also measured
vertically and tangentially with respect to the colonic
wall. The larger diameter was used as size. If there
was no correlate on CT, the PET lesion was considered
a positive ﬁnding if it was regarded as a focal lesion
(Figs. 1, 2, 3). In this case the size was obtained from
colonoscopy or if totally resected, from the histological
examination.
The quantitative analysis was performed for each visual
colorectal FDG uptake and included the measurement
of the maximum standardised uptake value (SUVmax)a n d
mean standardised uptake value (SUVmean) within a volume
that contains only voxels with SUV ≥50% of SUVmax.
In addition, the volume of the FDG uptake was
measured as so-called metabolic volume or volume of
interest (VOI). Currently there is no rationale and no
standardisation which border (isocontour) should be used
to deﬁne the VOI. Therefore, we determined the VOI in
relation to six isocontours deﬁned by absolute thresholds
(SUV=4, 7, 10) and relative thresholds depending on the
SUVmax (SUV=25%, 50%, 75% of SUVmax). The value
SUV=4 was chosen as the lowest limit for the absolute
threshold because the physiological SUVmax of the liver
is in this range. The other cut-off values were equidis-
tantly but otherwise arbitrarily chosen.
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Fig. 1 Incidental focal colorectal FDG uptake in the sigmoid
colon (carcinoma (arrow)) in a 57-year-old man on low-dose PET/
CT performed for follow-up after resection of a seminoma. A
rotating maximal intensity projection (MIP) (a) allows for screening
for focal FDG uptakes that are evaluated further on the multiplanar
reconstructions (here axial PET (b), axial low-dose CT (c), axial
low-dose PET/CT (d). Besides stool, sphincters and inﬂammation,
the urinary tract (here diverticulum of the bladder (arrowhead 1))
and focal colonic collapse (arrowhead 2) constitute the only
physiological pitfalls. Any shortcomings, however, can mostly be
differentiated from masses based on CT anatomy and the maximum
standardised uptake value (SUVmax). The SUVmax of 24.6 for the
lesion in the sigmoid colon (arrow) is a trigger for colonoscopy
(Fig. 5)
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Fig. 2 Incidental focal colorectal FDG uptake in descending colon
(carcinoma (arrow)) in a 72-year-old man on low-dose PET/CT
(performed for evaluation of the glucose metabolism in a
hepatocellular carcinoma (HCC) as surrogate for dedifferentiation/
grading. The maximum standardised uptake value (SUVmax) of 14.4
is a trigger for colonoscopy (Fig. 5)
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Fig. 3 Incidental focal colorectal FDG uptake in the sigmoid colon
(low-grade adenoma (arrow)) in a 66-year-old man on contrast-
enhanced PET/CT performed for staging of oesophageal cancer. The
maximum standardised uptake value (SUVmax) of 9.1 is a trigger for
colonoscopy (Fig. 5)
2277The SUV is normalised for activity injected per
body weight according to the formula: SUVmax/mean =
maximum/mean VOI activity [Bq/ml] / dose injected
per patient’s weight [Bq/g] with g = ml for a tissue density
of 1 g/ml.
Statistical analysis
Masses were deﬁned as relevant if ≥10 mm in maximum
diameter as measured by CT or by colonoscopy or
histological examination, or if they revealed high-grade
dysplasia, or were cancerous in the histological examination.
1. The inter-observer agreement in the decision to send
the patient to colonoscopy (ratings: 3, 4, 5) or not
(ratings: 1, 2) was determined by Cohen’s kappa. P
values of kappa below 0.05 indicate a statistically
signiﬁcant difference from only chance agreement.
2. The performance of PET, low-dose PET/CT and
contrast-enhanced PET/CT in detecting mass-positive
segments was compared by the area under the receiver
operating curve (ROC) for each reviewer as well as for
both reviewers by averaging their ROC ratings to a
common rating.
3. The per-segment performance of PET, low-dose
PET/CT and contrast-enhanced PET/CT (sensitivity,
speciﬁcity, negative predictive value (NPV), positive
predictive value (PPV)) was determined with the
dichotomised outcome of histological ﬁndings.
4. Univariate and multivariate logistic regression analy-
ses were used to ﬁnd cut-off parameters to discern the
two outcome groups mentioned above.
5. The SUVmax were compared with non-parametric
analysis of variance and Mann–Whitney U tests.
Local p values for the tests done in pairs are given
without adjustment. After applying Bonferroni adjust-
ment to avoid an increasing probability of a type I
error, p values stay below 0.05—the global alpha for
this study.
6. Finally, PET performance characteristics were deter-
mined for a cut-off that included all carcinomas and
adenomas with high-grade dysplasia (SUVmax≥5).
Statistical Analysis was performed by using a statistical
software package (SPSS Inc., version 16.0, Chicago,
USA).
Results
Patient demography
In total, 84 patients (18 female, 66 male) aged 41–91
(mean 65±10 years), who had a total colonoscopy (n=79)
or a sigmoidoscopy (n=5) as standard of reference for in
total 79   6 þ 5   2 ðÞ ¼ 484 colonic segments, were
included in this study. In one case, in which a tumour
stenosis in the proximal rectum hindered a full colonoscopy,
the postoperative colonoscopy was used as standard of
reference for the colonic segments that were preoperatively
not assessable. All sigmoidoscopies were performed instead
of colonoscopies due to palliative situations.
Reasons for colonoscopy/sigmoidoscopy referral were:
initial staging (n=14) or follow-up (n=5) of colorectal
cancer, a CUP syndrome (n=15) or incidental focal
colorectal FDG uptakes (n=50).
Patients with CUP syndrome
The 15 patients with CUP syndrome had malignant
lesions at the following sites: liver (n=6), lymph nodes
(n=4), bone (n=3), liver, lungs and bones (n=1) and
seminal vesicle (n=1). Histological examination was
available in 13 cases and revealed adenocarcinoma (n=
8), epithelial cancer (n=3), anaplastic carcinoma (n=1)
and remained unclear in one case (n=1) with osteolytic
bone metastases. In 4 patients the hepatic lesions turned
out to be the primary cancer (hepatocellular carcinoma
(n=1) and cholangiocarcinoma (n=3)). In the remaining
patients PET/CT found the primary cancer in 55% (6/
11) at the following sites: oesophagus (n=1), colon (n=
1), nasopharynx (n=1), tonsil (n=1), vulva (n=1) and
urinary tract (n=1). Three primary malignancies (breast
cancer (n=2) and prostate cancer (n=1)) were not
visualised in PET. The origin of hepatic metastases in
one patient and of osteolytic bone metastases in another
patient remained unclear.
Incidental focal colorectal FDG uptakes
Incidental focal colorectal FDG uptakes were observed in
2.1% (in 50 out of 2,338 patients not scanned for
colorectal cancer or CUP). In 50% (25/50) the incidental
focal colorectal FDG uptake turned out to be a relevant
mass on colonoscopy and even cancer in 16% (8/50).
Per-lesion analysis
In total, endoscopy revealed 59 relevant masses (36
adenomas and 23 carcinomas) in 43 out of 84 patients.
Histological examination of the adenomas revealed in 3%
(1/36) no dysplasia, in 69% (25/36) low-grade dysplasia,
and in 28% (10/36) high-grade dysplasia (Fig. 4).
PET visibility for relevant masses totalled 90% (53/
59): 83% (30/36) for relevant adenomas (mean size
(range) 15±5 (9–25) mm) and 100% (23/23) for
carcinomas (mean size (range) 35±20 (8–80) mm). PET
failed to visualise 10% (6/59) of relevant masses. All
masses not visualised on PET were adenomas. Three of
the six FDG-negative adenomas were in one patient and
showed high-grade dysplasia (two ≥10 mm, one 3 mm).
The other three FDG-negative adenomas were in 3
2278different patients, measured ≥10 mm and revealed low-
grade dysplasia. False-positive FDG uptakes totalled 45%
(48/107), most (67%) had stool as correlate on CT and
most(85%)werelocatedinthecaecum,sigmoidorrectum
(Fig. 4). Using the CTcomponent, the reviewers correctly
identiﬁed 85% (41/48) of false-positive FDG uptakes and
15% (7/48) were falsely misinterpreted as masses.
The SUVmax increases with the degree of malignancy,
from adenomas with low- and high-grade dysplasia
(SUVmax ¼ 9.7   6.9 and SUVmax ¼ 11.6   4.1) to carci-
nomas SUVmax ¼ 12.9   6.8 ðÞ (Fig. 5). The SUVmax of
false-positive FDG uptakes (n=48) were signiﬁcantly
lower SUVmax ¼ 7.4   3.8 ðÞ than those of adenomas with
high-grade dysplasia SUVmax ¼ 11.6   4.1 ðÞ and carcino-
mas SUVmax ¼ 12.9   6.8 ðÞ (Fig. 5). SUVmax and SUVmean
were found to be the best parameters for distinguishing
false-positive (FP) from true-positive (TP) lesions. The
SUVmean correlates with the SUVmax (r=0.97, n=107
(59 TP and 48 FP)) but shows less difference than the
SUVmax between false-positives and masses. Therefore,
the isocontour-independent SUVmax was favoured as the
cut-off.
In all carcinomas (n=23) and adenomas with high-
grade dysplasia (n=10) the SUVmax was ≥5 (Fig. 5). In
order to include all carcinomas and adenomas with high-
grade dysplasia this value was used as cut-off in the
comparison between the reviewer-dependent and cut-off-
based analysis.
Endoscopy (n=59) PET (n=107 (101 positive
(53 TP, 48 FP) + 6 FN)) Dysplasia n Size
† [mm] 
1 -
low-grade 25
Adenoma* 
Hyperplasia
high-grade 10 } 36 15±5 (9-25)  83% (30/36) 
Carcinoma  23 35±20(8-80) 100%  (23/23) 
Total  59 24±17(8-80) 
TP
90% (53/59) 
3 high-grade 
(two ≥10mm) 
in one 
patient  FN  10% (6/59) 3 low-grade 
(all ≥ 10  mm)  in 3 patients 
stool 67% (32/48)
collapse 8% (4/48)
inflammation 10%  (5/48) FP  45% (48/107) 
FP mass  15% (7/48)  
*adenomas ≥   10 mm/with high-grade dysplasia. 
maximum size (mean    SD (range)) measured on CT if visible; if not visible the size was obtained from the 
colonoscopy report. 
TP=True-positive, FP=false-positive, FN=false negative.
Transverse colon
4 Adenomas
1 Carcinoma
2 FP 
1 FN
Descending colon
5 Adenomas  
1 Carcinoma  
2 FP 
3 FN 
Ascending colon
3 Adenomas 
2 Carcinomas 
3 FP 
Sigmoid colon
14 Adenomas  
4 Carcinomas 
13 FP 
2 FN  Rectum
7 Adenomas  
1 Hyperplastic mucosa (20mm)
15 Carcinomas 
11 FP 
Caecum 
2 Adenomas 
0 Carcinoma 
17 FP 
†
‡
‡
+  _
Fig. 4 Summary of ﬁndings
2279Per-segment analysis (accuracy)
The performance of PET (subjective interpretation vs. cut-
off-based analysis), low-dose PET/CT and contrast-
enhanced PET/CT is summarised in Table 1:A sr e ﬂected
by the area under the curve low-dose PET/CT proved
superior to PET but was not inferior to contrast-enhanced
PET/CT. The use of an SUVmax≥5 as a cut-off, which
included all carcinomas and adenomas with high-grade
dysplasia, resulted in a better per-segment sensitivity and
Table 1 Performance of FDG-PET/CT in the detection of relevant colorectal neoplasms (adenomas ≥10 mm, with high-grade dysplasia or
cancer)
Per Patient Segment Lesion (Fig. 4)
PET/CT PET PET/CT PET
Reviewer Reviewer Cut-off
(SUVmaxQ5)
Low dose Normal
a Reviewer Cut-off
(SUVmaxQ5)
n=84
a n=484
b n=398 n=404 n=59 n=101
Incidence 51% (43/84) 11% (54/484) 11% (42/398) 12% (49/404) (in endoscopy) (in PET: 53TP,
48FP)
Agreement
c 89% 91% 92%
AUC
d
R1 0.845 0.882 0.875
R2 0.877 0.887 0.888
R1+R2 0.899 0.925 0.929
Sensitivity
e 91% (39/43) 81% (44/54) 89% (48/54) 76% (32/42) 82% (40/49) 90% (53/59) 94% (50/53)
f
Speciﬁcity
e 80% (33/41) 93% (399/430) 93% (401/430) 97% (345/356) 97% (344/355) – 35% (17/48)
NPV
e 89% (33/37) 98% (399/409) 99% (401/407) 97% (345/355) 98% (344/353) – 85% (17/20)
PPV
e 83% (39/47) 59% (44/75) 62% (48/77) 74% (32/43) 78% (40/51) 52% (53/101) 62% (50/81)
Accuracy
e 86% (72/84) 92% (443/484) 93% (449/484) 95% (377/398) 95% (384/404) – 66% (67/101)
aNormal:=contrast enhanced with full CT dose
bSegments with a standard of reference = 79   6 colonoscopy ðÞ þ 5   2 sigmoidoscopy ðÞ
cIn the decision to send the patient for colonoscopy (ratings: 3,4,5) or not (ratings: 1,2) (kappa=0.630; 0.605; 0.681; p=0.000)
dArea under the curve (AUC) of the receiver operating characteristic curve (ROC) separate for each reviewer (Ri) and for both reviewers (R1+R2) with
averaged ratings
eObtained from the averaged ratings of two independent reviewers or via the cut-off SUVmax≥5
f3 adenomas with low-grade dysplasia 12±2 mm in size would have been additionally missed with the cut-off SUVmax≥5
7.4±3.8
9.7±6.9
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12.9±6.8
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Fig. 5 Maximum standardised uptake value (SUVmax) in relation
to histological examination. The cut-off SUVmax≥5( red line)
includes the detection of all carcinomas and adenomas with high-
grade dysplasia, provides higher sensitivity and NPV than the PET
and PET/CT reviews (Table 1), and allows for computer-aided
detection
2280negative predictive value than the average PET and PET/
CT reviews (sensitivity 89% vs. 81% and 76–82%; NPV
99% vs. 98% and 97–98%) (Table 1).
Discussion
There is compelling evidence to support screening
average-risk individuals aged over 50 to detect and
prevent colorectal cancer [2, 3, 8, 13]. By sparing bowel
cleansing and distension, by displaying only relevant
lesions requiring polypectomy or resection, by taking
advantage of computer-aided detection via a standardised
cut-off, and by increasing the accuracy in detecting extra-
colonic pathological features, PET/CT could surpass CT
and MR colonography for colorectal screening.
Clinical impact
Multiple studies have already documented the value of PET/
CT for primary staging, restaging, and follow-up of patients
with colorectal cancer [14, 15]. Based on its therapeutic
impact, its ﬁrst-line use is increasingly recommended for
staging and restaging [15]. For detecting recurrence of
colorectal cancer, PET/CT can be more sensitive than
tumour markers, so that surveillance of asymptomatic and
even tumour-marker-negative patients with PET/CT seems
plausible [14, 16–18], in particular when taking into account
that PET/CT allows for comprehensive “TNM” follow-up
in one examination that is probably more accurate than CT
and colonoscopy together. Replacing CT and colonoscopy
by PET/CT also seems plausible for evaluation of asymp-
tomatic average-risk patients who present with raised
carcinoembryonic antigen (CEA) which indicates a malig-
nancy in 20% with 75% outside the colon [19].
The study suggests that colorectal cancer is always
visualized in PET, here with a mean SUVmax of 12.9±6.8
(range 5.7–29.6) (n=23) (Fig. 5) in accordance with the
literature SUVmax ¼ 12.6   4.9 ðÞ (n=51) [20–24].
We found that the cut-off-based PET analysis is more
accurate than the reviewer-dependent analysis (Table 1).
This ﬁnding in conjunction with the low incidence of focal
colorectal FDG uptakes 2.1% (literature, 2.2% (628 out of
28,253 patients)) but their high predictive value for a mass
of 62% (here with the cut-off SUVmax≥5) (literature, 73%
(254 out of 349))—of which 46% (literature, 33%) were
even cancer [20–22, 25–32]—indicates the recommenda-
tion that all patients with focal colorectal FDG uptakes
with SUVmax≥5 should automatically undergo a colono-
scopy. In other words the overall rate of false-positive
FDG uptakes resulting in unnecessary colonoscopy in
0.6% should be accepted for the beneﬁt of detecting
masses in 1.6% including even cancer in 0.5% [20–22,
25–32]—in particular if colonoscopy is recommended for
screening anyway.
In our study PET/CT incidentally detected additional
colorectal cancerin 0.3%(8/2,338)(Figs. 1,2,3)andfound
the primary cancer in the patients with CUP syndrome in
55% (6/11). Ishimori et al. [33] found colorectal cancer as
an additional primary malignancy in 0.2% (4/1,912) and
otherprovencarcinomasin1%includingcancerin thehead
and neck (n=1), thyroid (n=6), lung (n=7), lung and
thyroid (n=1), oesophagus (n=2), breast (n=2) and bile
duct (n=1)[33]. We did not evaluate the value of PET/CT
in detecting relevant extra-colonic pathologies. But we
could demonstrate its value in detecting the primary cancer
in patients with CUP syndrome as a surrogate for its
potential in detecting relevant extra-colonic pathologies.
PET/CT performed as PET/CT colonography on a
cleansed and distended colon [11] as well as on a non-
cleansed, only distended colon [12] is also feasible. This
has been proposed for patients with an incomplete
colonoscopy. Under optimal conditions in a screening
setting with a fully cleansed and distended colon, CT
colonography is so accurate that the additional value of
PET is minimal. Therefore, we evaluated the value of
PET/CT in a worst-case scenario i.e. in a non-cleansed and
non-distended colon imaged with minimal CT-dose and
without contrast material.
Screening issue
Acceptance and compliance
Although the average lifetime risks of diagnosing and
dying of colorectal cancer are 5.7% and 2.5%, respectively
[34], and although a majority of cases of colorectal
cancer can be prevented with colonoscopic removal of
the precursor adenomatous polyp [2–4], compliance with
colonoscopy is abysmal. Recently, a regional colono-
scopy screening programme demonstrated a disappoint-
ingly low participation rate of 1.5% despite the beneﬁts
and quality of service [35]. On the other hand, the prog-
ramme underlined the efﬁcacy of screening. Colorectal
masses were found in 26% (14,140 out of 54,491) of
asymptomatic participants. Cancer was found in 1.3% (692
out of 54,491).
In a CT colonography screening study including 1,452
subjects, the participation rate was 28% [36]. CT
colonography is considered less painful and less difﬁcult
than colonoscopy and is preferred over colonoscopy [37–
39]. Also MR colonography with limited bowel prepara-
tion was preferred over colonoscopy due to limited bowel
preparation and less pain [40]. However, discomfort
associated with cleansing and air ﬁlling is still an issue
in colonography [36–38], probably impacting compliance
with an interval screening programme.
A non-invasive method without cleansing, colon
distension and contrast material might possibly enhance
compliance with a screening programme. Thus, especially
in the case of colorectal cancer with a dwell time of
10 years in the adenoma–carcinoma sequence [9], com-
pliance with a screening programme may compensate for
less sensitivity of a single interval examination. Thus, a
higher participation rate in a PET/CT programme com-
2281bined with a high accuracy in detecting relevant extra-
colonic ﬁndings could compensate for the low PET
sensitivity in the detection of small polyps—if small
polyps are relevant at all [10].
In CT colonography, relevant extra-colonic ﬁndings
requiring subsequent medical or surgical interventions
were observed in 3.2% (109/3,376) in a screening
population [41–43]. Typical examples of important ﬁnd-
ings are aortic aneurysms, solid renal or hepatic masses,
adrenal masses, suspicious lung nodules, hydronephrosis,
lymphadenopathy, and ovarian cysts [41, 42, 44]. PET/CT
is more speciﬁc than contrast-enhanced CT in character-
ising hepatic masses, adrenal masses, lung nodules and
ovarian cysts. Thus, it is more cost-effective than CT
colonography for which a mean cost of US $27±8 per
patient was calculated for further evaluation of extra-
colonic ﬁndings [41–43, 45, 46].
Of course, currently the limited availability of PET/CT
and its high costs hinder its use for screening. However, if
the costs for a non-invasive, 5-min PET/CT examination
arelowerthanthoseforthesumoftheexaminationsneeded
to exclude the same amount of cancer entities in the early
stage (e.g. MRI, CT, endoscopies for the hollow organs,
mammography, inspection for melanoma), the demand for
PET/CT as an all-in-one (multiorgan screening) examina-
tion might increase.
Target
It is generally accepted that in 80–85% of cancer cases,
adenomas constitute the precursors for colorectal cancer
[2, 3, 9] and that the progression from adenoma to
carcinoma takes 10 years or more [9, 10]. Thus, removal
of adenomas at regular intervals in an appropriate time
frame constitutes a simple and effective cancer prophy-
laxis. The fact that the prevalence of polyps is high (30–
50%) after age 50 years, increases with age, and that only
approximately 3% of the adenomas become malignant [9,
10], render the introduction of a cut-off value in polyp
screening reasonable to avoid unnecessary polypectomies.
In CT colonography, the cut-off is related to size and
amount relative to 10 mm [26–28]. The sensitivity of
PET/CT in visualising polyps ≤10 mm is only 21% (46
out of 219), and the 66% (163 out of 247) sensitivity in
detecting masses >10 mm is disappointing compared with
that of CT colonography (sensitivity 94%) [24, 27, 30,
47–49]. Despite the high molecular sensitivity of PET for
the tracer (10
−11–10
−12 mole/L), smaller polyps can be
negative on PET if their signal is spatially and temporally
averaged to normal in the 5 mm
3 image voxel and 3-min
acquisition time per bed position (partial volume artefact).
Hence, it is clear why PET fails to visualize smaller
polyps whose signal is blurred in the colonic peristalsis
and averaged with that of the signal void of surrounding
air in the colon. In this study with improved spatial
resolution (4.5 mm in the axial plane), the detection rate
for polyps ≥10 mm was 83% (30/36). Current PET/CT
provides a higher spatial resolution (2.5 mm) and detector
gain (detected counts per second and applied activity
(currently 9.1 kcounts/sMBq)) as well as a faster scanning
(5 min per whole body), so that detecting smaller polyps
may increase as technology progresses and partial volume
effects decrease. But the spatial resolution is limited by
the linear range of the random walk of the positron, which
is a mean of 0.2 mm (maximum 2.4 mm) in the case of
18F. However, lower spatial resolution can be compen-
sated by a higher FDG uptake (hot spot phenomena) so
that smaller neoplasms will be detected if their SUVmax is
large enough to be differentiated from the background
noise (Figs. 1, 2, 3).
Smaller, non-growing and therefore non-glucose-con-
suming polyps are usually not visible on PET [24]. Thus,
with metabolic information, PET/CT is inherently more
promising than CT colonography in identifying polyps at
risk of malignant transformation or already transformed
to cancer. Van Kouwen et al. [50] showed in 24 patients
with familial adenomatous polyposis (FAP) that the
metabolic PET information identiﬁed FAP patients
requiring additional examinations to rule out cancer and
justiﬁed in others a more conservative approach. Other
studies also showed a difference in the FDG uptake
between polyps and cancer (SUVmax: 9.1   3.6 for polyps
n ¼ 88 ðÞ vs. 12.6   4.9 for carcinomas n ¼ 51 ðÞ )[ 20–24].
This study conﬁrms the correlation between the degree of
malignancy and glycolysis rate reﬂected by SUVmax
(Fig. 5). The correlation between the degree of malignancy
and glycolysis provides the rationale for an SUVmax-based
cut-off.
Computer-aided detection
Computer-aided detection also requires a cut-off. Using a
cut-off (SUVmax≥5), that includes all carcinomas and all
adenomas with high-grade dysplasia (Fig. 5), resulted in
a higher sensitivity and negative predictive value than the
reviewer-dependent analysis of the contrast-enhanced
PET/CT (sensitivity 89% vs. 82%, NPV 99% vs. 98%)
(Table 1). However, the lower speciﬁcity of PET in
comparison with PET/CT (93% vs. 97%) (Table 1)
demonstrates that the PET ﬁndings should be still
anatomically correlated with the CT to better identify
false-positives as stool, gastric or anal sphincters or parts
of the urinary system. Administration of contrast did not
improve the accuracy (95%) and speciﬁcity (97%) of
PET/CT (Table 1). Thus, for screening purposes contrast
media is not needed and in the case of an equivocal
ﬁnding in the colorectum the patient should be sent for
colonoscopy instead of receiving contrast material and a
second CT scan.
We tested different PET values and their combinations
for separating true-positives (TP) from false-positives
(FP). But the metabolic volumes (VOI) as well as the
ratios SUVmax/mean/metabolic volumes, reﬂecting a kind of
density, were inferior to the SUVmax in the differentiation
between TP and FP. In principle, the focality of an FDG
uptake visualised on 2D maximum intensity projections
2282should mathematically be deﬁnable even in 3D. The
volume bordered by an SUVof 50% of the SUVmax is the
3D correlate to the full width at half maximum (FWHM)
in 1D but also was not useful to improve the speciﬁcity.
We have also taken into account the slope (gradient) in the
SUV distribution by using the differences (Δ) between the
VOIs in the ratios SUVmax/mean/ΔVOI. But this cut-off
also failed to improve the speciﬁcity in differentiating TP
from FP.
The failure in ﬁnding a better cut-off could possibly
be explained by the fact that 59% (50/84) of the
patients were already selected through the focal
criterion, which was visually deﬁned. In our study
the 50 patients with incidental focal colorectal FDG
uptake were visually ﬁltered out from 2,338 patients. It
is conceivable that this pre-selection can be performed
by a computer, which ﬁlters out only the patients with
an abdominal FDG uptake over a certain cut-off. Then,
the urinary system as the only physiological cause of
increased FDG uptake in the abdomen needs to be
excluded by a human interface. But the urinary system
can possibly also be identiﬁed by a computer based on
SUVmax criteria (e.g. high value and homogeneous
distribution) in conjunction with anatomical criteria (e.g.
localisation and shape). Consequently, computer-aided
detection of focal FDG uptakes in PET/CT is easier to
realise than computer-aided detection on CT/MR colo-
nography or even colonoscopy.
Dose issue: detection vs. initiation of cancer
Whether in the clinical context of staging, preoperative
evaluation, follow-up and evaluation of screening ﬁnd-
ings or in a context of screening risk groups (e.g.
smokers) or even asymptomatic persons not at risk,
PET/CT is probably most sensitive in the detection of
malignancies [25, 29, 51, 52]. This is supported by the
fact that PET/CT is used if not primarily at least as ultima
ratio to ﬁnd the primary cancer in patients with CUP
syndrome [53].
Combined PET and tumour marker screening revealed
cancer in 1.5% (986 out of 67,510) of asymptomatic
people. Of these, PET detected 668 cancer (sensitivity
68%). They were mostly cancers in the thyroid (25%),
colon (23%), lung (21%) and breast (10%) [54–60]. When
additionally using the CT component, which is automati-
cally included nowadays for attenuation correction, small
lung cancer as well as non-oncological pathological
features can also be detected.
Considering the ratio of extra-colonic pathological
features to colonic malignancies, PET/CT is expected to
detect more extra-colonic pathological features than miss
colonic malignancies. Thus, the advantage of PET/CT in
detecting pathological features in and outside the colon
outweighs both its weakness in detecting smaller, less
malignant polyps as well as the 0.024% radiation risk of
initiating a malignancy in 20–30 years. The radiation risk
is calculated from 0.005% /mSv   0.34mSv CTdose ðÞ ðþ
0.012mSv/MBq   370MBq (PET dose)) [61]. Cancer is
responsible for death in more than 25% of the population
in industrialised nations [62]. The probability of detecting
cancer increases with age while the probability of dying
from radiation-induced cancer decreases with age due to
the latency period of 20–30 years. Therefore, the
individual beneﬁt-to-cost ratio of PET/CT screening
increases with age. In the worst case, if both the
radiation-induced cancer mortality (0.024%) and the
natural cancer mortality (25%) are not age-related, to be
justiﬁed PET/CT needs to prevent more than 0.6% of the
natural 25% of cancer mortality.
Limitation and future work
The study is retrospective. Further prospectively designed
studies should clarify:
– If omission of oral contrast reduces the FDG uptake in
the normal colonic wall and its excretion into stool
(direct or via dissociation of FDG-loaded mucosa
cells) [63],
– If the cut-off is dependent on the scanner type and
requires a cross-calibration between different scanners
[64],
– If an intrinsic normalisation to the mean SUV of the
liver improves the accuracy of the cut-off [65], and
– If low dose, non-enhanced PET/CT is more cost-
effective than CT in identifying (detecting and classi-
fying) relevant extra-colonic pathological features [66].
Another limitation of this retrospective study is the
selection bias. Only patients with a high likelihood of
being further evaluated with colonoscopy were ﬁltered
out of the PET database of 4,004 reports. Thus, the
database was only browsed for patients referred for initial
staging or follow-up of colorectal cancer or for further
evaluation of a CUP syndrome or incidental focal
colorectal FDG uptakes. The other, mostly oncological
PET patients were unlikely to undergo additional screen-
ing colonoscopy within the next 3 months after the PET/
CT. Therefore, we limited the search only to the sub-
group described above and did not check if other PET
patients coincidentally underwent a colonoscopy. How-
ever, by including patients with CUP syndrome as a
“normal collective” (without a colorectal mass), dividing
the colon into six segments, considering each segment as
independent and performing a per-segment analysis, we
sought to lower the incidence (43/84 (51%) per patient
vs. 54/484 (11%) per segment) and thereby to minimise
any bias that might be associated with the patient
selection. A prospective study including a normal
collective undergoing PET/CT followed by colonoscopy
would overcome the selection bias. However, the mean-
ing of the SUVmax as cut-off should not be biased by the
patient selection.
2283Conclusion
FDG-PET/CT provides promising accuracy for colorectal
mass detection. Low dose and lack of iodine contrast do
not impact the accuracy. A standardised PET cut-off (e.g.
SUVmax≥5) improves the accuracy.
Prospective studies with more polyps and improved
PET technology seem to be warranted—not only to obtain
a test data set for ﬁnding a better cut-off, but also to ﬁgure
out if PET/CT is sufﬁcient for ruling out relevant color-
ectal neoplasms.
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